Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTVandana SinghSat, June 27, 2026 at 12:01 PM GMT+2 6 min readBenzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.Absci Corporation stock is trading higher on Wednesday after the company reported positive interim Phase 1 results for its investigational anti-prolactin receptor antibody, ABS-201, while also pricing a $100 million underwritten stock offering to support continued development of the program.ABS-201 Shows Favorable Safety And Pharmacokinetic ProfileThe clinical-stage biopharmaceutical company said the early-stage trial findings demonstrated a favorable safety, pharmacokinetic, and immunogenicity profile for ABS-201, supporting further evaluation in androgenetic alopecia (AGA) and endometriosis.Somaratne added that the company plans to continue evaluating ABS-201 in the ongoing multiple ascending dose, or MAD, portion of the HEADLINE study in AGA patients and intends to begin a Phase 2 trial in endometriosis later this year.Don't Miss:A single bad hire can set a startup back years. Here are the 5 hires founders most often misjudge — and whyStill Learning the Market? These 50 Must-Know Terms Can Help You Catch Up FastTrial Advances Into Multiple Ascending Dose PortionThe ongoing Phase 1 study is a randomized, double-blind, placebo-controlled trial assessing the safety and pharmacokinetics of ABS-201 in healthy volunteers with and without AGA.Interim data include 32 healthy adults enrolled across four single ascending dose cohorts evaluating intravenous doses of 150 mg, 450 mg, 900 mg, and 1,800 mg.According to blinded aggregate data through the June 8, 2026, cutoff, ABS-201 was generally well tolerated.No serious adverse events were reported. Most treatment-emergent adverse events were mild, with a single moderate headache in one participant that investigators deemed unlikely to be related to treatment.Headache was the most commonly reported adverse event, occurring in four participants.Trending: Avoid the #1 Investing Mistake: How Your 'Safe' Holdings Could Be Costing You Big TimePharmacokinetic findings indicated that ABS-201 may have a half-life of at least 65 days, potentially supporting dosing two or three times over a six-month period, subject to confirmation in ongoing follow-up.The company also reported no apparent impact of anti-drug antibodies on pharmacokinetics in the single ascending dose cohorts.Raises Capital To Support ABS-201 ProgramSeparately, Absci announced the pricing of an underwritten offering of 13.5 million shares at $7.41 per share.The company expects gross proceeds of approximately $100 million. Absci said it intends to use the net proceeds to advance ABS-201 across androgenetic alopecia and endometriosis, as well as for working capital and other general corporate purposes.Terms and Privacy PolicyEU DSA contactPrivacy & Cookie SettingsMore Info